Latest studies
- RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesitySlovakia - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Slovakia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder
This study is looking at a new medicine called Ulotaront for adults with generalised anxiety disorder. We want to see if it helps reduce anxiety and if it's safe to use. Some people will get the new medicine, and others will get a dummy pill.
generalised anxiety disorderSlovakia - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathySlovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.
Major Depressive DisorderSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Obesity, Chronic Kidney disease, Type 2 Diabetes, Cardiovascular Diseases, Overweight or Obesity, OverweightSlovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
J3P-MC-FTAF: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
This study is testing a new medicine, LY3871801, for adults with rheumatoid arthritis. It's a research study to see how well the medicine works and if it's safe compared to a dummy pill. We hope to find new ways to help people with this condition.
Rheumatoid ArthritisSlovakia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
This study is testing a new medicine, GB-0895, for adults with severe asthma that isn't well controlled by current treatments. We want to see if it can reduce severe asthma attacks and improve breathing and quality of life over 52 weeks, compared to a dummy medicine.
Severe uncontrolled asthmaSlovakia - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
Breast CancerSlovakia - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseSlovakia - RecruitingPHASE2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study tests a new medicine, BI 1815368, for people with diabetic macular edema (DME), an eye condition linked to diabetes. It aims to see if the medicine improves sight and to find the best dose. Participants take tablets for about 11 months.
Macular EdemaSlovakia - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
This study looks at a new version of Eylea (a medicine for eye problems) to see if it's safe and works well for people with blurry vision caused by fluid build-up at the back of their eye. It compares the new version to the standard treatment.
Macular edema secondary to retinal vein occlusionSlovakia - Active not recruitingPHASE3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
This study compares two drug combinations – camizestrant with palbociclib, and anastrozole with palbociclib – for advanced breast cancer. It's for patients whose cancer has specific hormone features and hasn't yet been treated for its advanced stage. The goal is to find a better first treatment.
ER-Positive HER2-Negative Breast CancerSlovakia - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
Triple Negative Breast NeoplasmsSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
This study is testing a new medicine, secukinumab, for people with ongoing shoulder pain caused by rotator cuff problems. It compares the medicine to a dummy treatment (placebo) to see if it helps reduce pain and improve shoulder movement over 24 weeks.
Moderate to severe rotator cuff tendinopathySlovakia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
This study compares two existing medicines, Guselkumab and Risankizumab (also known as Skyrizi), for adults with Crohn's disease that is moderate to severe. It aims to see which medicine works better and is safer over time to help people feel much better.
Moderately to Severely Active Crohn’s DiseaseSlovakia - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisSlovakia - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisSlovakia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
This study is looking into a new medication called remibrutinib for people with a type of multiple sclerosis (MS) called Secondary Progressive MS (SPMS). It will check if the medicine is safe and helps slow down the disease.
Secondary Progressive Multiple Sclerosis (SPMS)Slovakia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
This study looks at new drug combinations for children with specific types of cancer (Ewing sarcoma or neuroblastoma) that have come back or not responded to previous treatment. It tests how safe and effective these combinations are.
recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastomaSlovakia - RecruitingPHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
This study looks at a new medicine, Baxdrostat, combined with an existing one, Dapagliflozin, for people with long-term kidney disease and high blood pressure. It aims to see if this combination can help protect the kidneys and heart better than Dapagliflozin alone.
Chronic Kidney Disease and HypertensionSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg.
This study compares a new vaginal ring delivery system for contraception with a commonly used birth control pill. It aims to see how well each prevents pregnancy and how safe and tolerable they are for women.
Prevention of pregnancySlovakia - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
This study is looking at a new medicine, EYE103, for people with a common eye condition called diabetic macular oedema (DME). It compares EYE103 with a standard treatment, ranibizumab, to see if it's safe and helps improve vision.
Diabetic Macular Edema (DME)Slovakia - Active not recruitingPHASE3
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study looks at a new medicine called survodutide for people who are overweight or obese. It checks if survodutide helps with heart health problems. Participants take the medicine weekly for up to 2 years, alongside diet and exercise advice.
ObesitySlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I8F-MC-GPGN: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
This study compares two medicines, tirzepatide and dulaglutide, for people with type 2 diabetes. It looks at how well they protect against serious heart problems like heart attacks and strokes. It's a big, important study to confirm which medicine is better for your heart.
Type 2 Diabetes MellitusSlovakia - Active not recruitingPHASE4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
This study is looking at whether a medicine called dupilumab can help adults with moderate to severe asthma keep their lungs working better over time. It compares dupilumab to standard asthma care to see if it can prevent lung function from getting worse. It's a long-term study.
AsthmaSlovakia - AuthorisedTherapeutic confirmatory (Phase III)
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
This study is looking at a new medicine called duvakitug for people with moderate to severe Crohn's disease. Researchers want to see if it helps keep the disease under control and is safe to use. It's a phase 3 study, meaning many people will take part.
Immune system diseasesSlovakia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
This study looks at a new medicine called sonelokimab for psoriatic arthritis. It checks how safe and helpful the medicine is over a long time for people who have already tried it in another study. Doctors will monitor side effects and overall health.
psoriatic arthritis (PsA)Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
This study looks at a new medicine called efgartigimod for adults with Bullous Pemphigoid. It's an ongoing study to see how safe and effective the medicine is long-term, and how well it helps manage symptoms and improve quality of life.
Bullous PemphigoidSlovakia - RecruitingPHASE3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.
OverweightObesitySlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery or Procedure (ANNEXA-RS)
This study is comparing a new medication called Andexanet Alfa to usual care. It's for patients who are taking blood thinners (like apixaban, rivaroxaban, or edoxaban) and need urgent surgery. The aim is to see if Andexanet Alfa helps stop bleeding during their operation.
Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.Slovakia - RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
This study compares a new medicine, PF-08046054, with a standard lung cancer treatment, Docetaxel. It's for adults with a certain type of lung cancer that has already been treated and has a specific marker called PD-L1.
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung CarcinomaSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis
This study compares a new medicine (BP16) with an existing one (Prolia®) for women with weak bones after menopause. Researchers will check if BP16 helps strengthen bones, how safe it is, and if the body reacts to it, over about a year and a half.
Post-Menopausal OsteoporosisSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
This study is testing a new combination medicine, CagriSema, for people with type 2 diabetes. It's looking at whether this combined medicine is better at controlling blood sugar and helping with weight loss than existing treatments, including its individual components, semaglutide and cagrilintide.
Type 2 diabetesSlovakia - RecruitingPHASE3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
This study looks at combining two medicines, mirikizumab and tirzepatide, for adults with ulcerative colitis (UC) who are also overweight or obese. The goal is to see if this combination helps UC symptoms improve and also leads to significant weight loss.
Ulcerative ColitisObesity or OverweightSlovakia - Recruiting
TrueLok Elevate PMCF Study
This study looks at a special tool called TrueLok Elevate for fixing skin wounds, ulcers, and soft tissue problems, especially on the lower leg. It helps mend bone and tissue by gently stretching them. It's for adults with long-lasting ulcers not getting better with usual treatments.
Wound of SkinUlcersSoft Tissue DefectSlovakia - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusSlovakia - RecruitingPHASE3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
This study looks at a new medicine called muvalaplin to see if it can lower the risk of heart attacks and strokes in people with high levels of a specific fat in their blood called Lp(a).
Elevated Lp(a)Atherosclerotic Cardiovascular Disease (ASCVD)Slovakia - Active not recruitingPHASE3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
This study looks at a new weekly injection, MET097, for adults who are overweight or have obesity. It checks how well it helps with weight loss and if it's safe. The study lasts for 84 weeks, focusing on participants without type 2 diabetes.
Obesity and OverweightSlovakia - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Slovakia - Active not recruitingPHASE3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is looking at a medicine called semaglutide for a liver condition called non-alcoholic steatohepatitis (NASH). Participants will receive either semaglutide or a dummy medicine. It's a long study, lasting about 5 years, with regular clinic visits.
Non-alcoholic SteatohepatitisSlovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
(22138) A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 3018250 in patients with symptomatic proximal deep vein thrombosis
This study is testing a new medicine, BAY 3018250, for blood clots in deep veins (DVT) in the legs. We want to see if it helps break down clots and reduce leg pain, while also checking for any serious side effects like bleeding.
Thrombolysis of symptomatic proximal vein thrombosisSlovakia - Active not recruitingPHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
This study is testing a new medicine, inclisiran, to see if it can prevent serious heart problems like heart attacks and strokes in people who are at high risk but haven't had one before. They are comparing it to a dummy medicine.
Primary Prevention of Atherosclerotic Cardiovascular DiseaseSlovakia - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
Chronic Lymphocytic LeukemiaSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This study is testing a new medicine, ABX464, for people with moderate to severe ulcerative colitis. Researchers want to see if it helps improve the gut lining and reduces symptoms after 8 weeks, and if it's safe to use.
Moderately to severely active ulcerative colitisSlovakia - Active not recruitingPHASE2
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
This study is looking at a new medication, TEV-48574, for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well different doses work over the long term and if they are safe.
Crohn DiseaseColitis, UlcerativeSlovakia - Active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
Ulcerative ColitisSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial
This study looks at how well a medicine called ocrelizumab works and if it's safe for people with multiple sclerosis (MS). It's for patients who have already been in similar studies with the same medicine.
Multiple sclerosis (MS)Slovakia - RecruitingPHASE3
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
This study is looking at a new medicine called N-Acetyl-L-Leucine for Niemann-Pick Disease Type C. It compares the new medicine to a dummy treatment (placebo) to see if it's safe and helps people aged 4 and older with this condition.
Niemann-Pick Disease, Type CSlovakia